Should the Phase 3 trial prove successful, ganaplacide/lumefantrine could be an alternative to artemisinin-based treatments, which are being increasingly challenged by resistant strains of malaria. Indeed, as the world faces emerging resistance to current malaria treatments, new drugs are critical.
Novartis And Medicines For Malaria Venture Make Important Progress On The Anti-Malarial Treatment Front
